NuGen Medical Devices Inc.: InsuJet Distribution Expands Across Canada

Toronto, Ontario--(Newsfile Corp. - April 24, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is please to report that distribution of The InsuJet will be expanded with increased availability across Canada connecting alongside health professionals.

"Following its Health Canada approval and our nationwide introduction at World Diabetes Day held on November 14^th, 2024, The InsuJet device is already making a measurable difference in diabetes care across Canada" commented Liang Lin, CEO of Nugen. "We have a wonderful testimonial, called Lilly's story that is both meaningful to the Company from a product adoption perspective while also illustrating the strong impact we are having on patient care."

Lilly's story. A teenager from Northern Canada diagnosed with diabetes at a young age, switching to InsuJet.

Click here to view Lilly's story: Why Lilly Anna loves InsuJet

Expanding Availability Across Canada

In the first quarter of 2025, InsuJet made its way into Canadian pharmacy retailers and distributors, including London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, and McKesson Canada. The newest distribution partner, Kohl & Frisch, and a national retail partner will begin offering InsuJet in their pharmacies by mid-April.

To further support accessibility and education, NuGen's exclusive distributor for Canada, Sol-Millennium has onboarded pharmacy adjudication partner MyRxCare and Greenshield Canada. These partnerships will help Canadian pharmacy retailers deliver education aimed at identifying Canadians with diabetes who could benefit from needle-free insulin administration.

Additionally, Sol-Millennium continues partnership with I Challenge Diabetes, a Canadian non-profit organization dedicated to supporting families living with diabetes. Their CEO and founder, Chris Jarvis-T1 Gold Medal Rower for Canada- will continue to promote and raise awareness of this innovative technology across the country.

Connecting with Healthcare Professionals

Further, Sol-Millennium will be attending several key pharmacy and healthcare conferences across Canada in 2025, and keep engaging with healthcare professionals: endocrinologists, primary care physicians, pharmacists, Certified Diabetes Educators (CDEs), and researchers. These events provide a platform to showcase the InsuJet device and highlight its benefits to a wide clinical audience.

Sol-Millennium also look forward to connecting directly with Canadian families living with diabetes, promoting a needle-free future, and gathering valuable feedback and testimonial opportunities. These engagements align with Sol-Millennium's mission of advancing patient care for those living with diabetes as well as future commitment to having InsuJet added to the Canadian Diabetes Guidelines.

Recent Past Conferences:
Diabetes Simplify (Toronto, ON - March 1^st)
Vendor Theatre (Toronto, ON - March 6^th)
Durham Care Diabetes Symposium (Oshawa, ON - April 5^th)
Familiprix (Quebec - April 11^th -12^th)

Upcoming Conferences:
Pharma Choice (Calgary, AB - April 25^th - 26^th)
2025 Pharmacy Trade Show - Pattison Food Group (Edmonton, AB - April 26^th)
Pharmasave (Vancouver, BC - April 29^th - 30^th)
2025 Diabetes Canada/CSEM Professional Conference (Toronto, ON - November 26^th - 28^th)

About Sol-Millennium Medical Group

Sol-Millennium Medical Group is a vertically integrated manufacturer of medical devices. With global operations and a commitment to deliver advanced, patient-friendly healthcare technologies, Sol-Millennium Medical partners with healthcare providers to improve outcomes and build a healthier tomorrow for all.

About NuGen

NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously. The Company is marketing and selling its next-generation InsuJet needle-free injection system designed to improve the lives of millions of diabetics. InsuJet is approved for sale in 42 countries around the world.

For further information, please visit:

Websites: www.insujet.com, and www.nugenmd.com

Instagram: @NuGenMD

Twitter: @NuGenMD

LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:
Liang Lin, Chief Executive Officer
[phone]
[e-mail]

Investor Relations:
Richard Buzbuzian
[phone]
[e-mail]

Notice Regarding Forward-Looking Information:

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249688

SOURCE: NuGen Medical Devices Inc.